TNF Pharmaceuticals Files Definitive Proxy Statement

TL;DR

TNF Pharma (formerly MyMD) filed its proxy statement. Standard stuff, shareholders vote soon.

AI Summary

TNF Pharmaceuticals, Inc. filed a definitive proxy statement (DEF 14A) on November 1, 2024. The filing relates to the company's proxy materials for its shareholders. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and prior to that, Akers Biosciences, Inc.

Why It Matters

This filing is a standard regulatory requirement for public companies to provide shareholders with information before a shareholder meeting, impacting corporate governance and shareholder voting.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing, which is a standard disclosure document for public companies and does not inherently present new risks.

Key Players & Entities

• TNF Pharmaceuticals, Inc. (company) — Registrant
• MyMD Pharmaceuticals, Inc. (company) — Former Company Name
• Akers Biosciences, Inc. (company) — Former Company Name
• 0001493152-24-043339 (filing_id) — Accession Number
• 20241101 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — Convertible Preferred Stock, par value $0.001 per share (the “Series D Preferre

Filing Documents

• formdef14a.htm (DEF 14A) — 792KB
• formdef14a_001.jpg (GRAPHIC) — 287KB
• formdef14a_002.jpg (GRAPHIC) — 287KB
• formdef14a_003.jpg (GRAPHIC) — 31KB
• formdef14a_004.jpg (GRAPHIC) — 80KB
• proxycard_001.jpg (GRAPHIC) — 2382KB
• proxycard_002.jpg (GRAPHIC) — 1305KB
• 0001493152-24-043339.txt ( ) — 6805KB

Executive Compensation

Executive Compensation 26 Audit Committee Matters 42 Proposal 2: The Incentive Plan Amendment Proposal 44 Proposal 3: The Auditor Ratification Proposal 53 Proposal 4: The Adjournment Proposal 54 Other Matters 55 Where You Can Find Additional Information 55 Annex A — Form of Incentive Plan Amendment A-1 TNF Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 623 Baltimore, MD 21205 (856) 848-8698 Proxy for Annual Meeting of Stockholders To be Held on November 25, 2024 Unless the context otherwise requires, references in this Proxy Statement to “we,” “us,” “our,” the “Company,” or “TNF” refer to TNF Pharmaceuticals, Inc., a Delaware corporation, and its consolidated subsidiaries as a whole. In addition, unless the context otherwise requires, references to “stockholders” are to the holders of our voting securities, which consist of: our common stock, par value $0.001 per share (the “Common Stock”); our Series D Convertible Preferred Stock, par value $0.001 per share (the “Series D Preferred Stock”); our Series F Convertible Preferred Stock, par value $0.001 per share (the “Series F Preferred Stock”); our Series F-1 Convertible Preferred Stock, par value $0.001 per share (the “Series F-1 Preferred Stock”); and our Series G Convertible Preferred Stock, par value $0.001 per share (the “Series G Preferred Stock”), in each case, entitled to vote at the annual meeting of stockholders of the Company (the “Annual Meeting”). Your proxy is solicited by the Board of Directors (the “Board”) on behalf of TNF Pharmaceuticals, Inc. to be voted at the Annual Meeting to be held on November 25, 2024, at the time and virtual location and for the purposes set forth in the accompanying Notice of Annual Meeting of Stockholders (the “Notice”) and at any adjou

View Full Filing

View this DEF 14A filing on SEC EDGAR